Top 10 Zaleplon (Sonata) Generic Manufacturers in Mexico

User avatar placeholder
Written by Robert Gultig

6 January 2026

Top 10 Zaleplon (Sonata) Generic Manufacturers in Mexico

The pharmaceutical market in Mexico has shown remarkable growth in recent years, driven by an increasing demand for generic medications, including Zaleplon, commonly known by its brand name Sonata. As of 2023, the Mexican generic pharmaceutical market is valued at approximately $4.6 billion, with projections indicating a compound annual growth rate (CAGR) of around 6% over the next five years. This growth is largely fueled by the rising prevalence of sleep disorders and the expanding healthcare infrastructure, which has bolstered the production and distribution of generic drugs across the country.

1. Laboratorios Pisa

Laboratorios Pisa is one of the leading generic drug manufacturers in Mexico, focusing heavily on the production of psychotropic medications, including Zaleplon. The company boasts a market share of around 12% in the Mexican generic sector, with an annual production capacity exceeding 300 million units.

2. Genomma Lab

Genomma Lab is a major player in the Mexican pharmaceutical landscape, with a diverse portfolio that includes various generic medications. The company’s annual revenue from generics reached approximately $300 million in 2022, and its market presence is bolstered by its strong distribution network.

3. Farmacéuticos S.A. de C.V.

Farmacéuticos S.A. de C.V. has established itself as a reputable manufacturer of generic medicines, specializing in sleep aids such as Zaleplon. The company has a production volume of around 50 million units annually, contributing to its significant market share in the generic segment.

4. Laboratorios Del Río

Laboratorios Del Río is known for producing a variety of generic medications, including Zaleplon. With a focus on quality and compliance, the company has captured approximately 8% of the market share in the generics sector, with annual production figures around 40 million units.

5. Grupo Neolpharma

Grupo Neolpharma is a prominent manufacturer with a strong emphasis on generics and biosimilars. The company’s revenues from generic drug sales amounted to $400 million in 2022, highlighting its importance in the Zaleplon market segment.

6. Sigma Alimentos

While primarily known for its food products, Sigma Alimentos has expanded into pharmaceuticals, producing generics like Zaleplon. The company reports a growing production capacity, with estimates indicating over 20 million units produced each year.

7. Farmacias similares

Farmacias similares operates a chain of pharmacies that not only sell but also produce generics, including Zaleplon. With a network of over 2,500 locations, they maintain a substantial market presence, contributing to the accessibility of generic medications.

8. Laboratorios Liconsa

Laboratorios Liconsa specializes in various therapeutic areas, including sleep disorders. The company has a production capacity of approximately 30 million units annually, and its strategic partnerships have helped increase its market share significantly.

9. Laboratorios Grin

Laboratorios Grin is recognized for its commitment to producing high-quality generics. With a production volume of around 25 million units for various medications, including Zaleplon, the company is steadily increasing its share in the generic drug market.

10. Productos Medix

Productos Medix is a notable manufacturer of generics in Mexico. With a focus on quality and competitive pricing, the company produces over 15 million units of Zaleplon annually, making it a key player in the generic pharmaceutical landscape.

Insights

The market for Zaleplon in Mexico continues to expand, driven by increasing consumer awareness of sleep disorders and the affordability of generic medications. With the Mexican generic pharmaceutical sector projected to grow at a CAGR of 6% and the total market reaching $4.6 billion, companies are ramping up production capacities and optimizing their distribution channels. As the demand for effective sleep aids rises, manufacturers are likely to invest more in research and development to enhance their product portfolios, ensuring they remain competitive in a rapidly evolving market landscape. The ongoing collaboration between manufacturers and healthcare providers will be crucial in meeting the increasing demand for generics like Zaleplon.

Related Analysis: View Previous Industry Report

Author: Robert Gultig in conjunction with ESS Research Team

Robert Gultig is a veteran Managing Director and International Trade Consultant with over 20 years of experience in global trading and market research. Robert leverages his deep industry knowledge and strategic marketing background (BBA) to provide authoritative market insights in conjunction with the ESS Research Team. If you would like to contribute articles or insights, please join our team by emailing support@essfeed.com.
View Robert’s LinkedIn Profile →